Digoxin toxicity

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 20 Aug 2025
Last updated: 12 Sep 2025

Summary

Definição

História e exame físico

Principais fatores diagnósticos

  • digoxin exposure
  • gastrointestinal symptoms
  • central nervous system symptoms
  • visual symptoms
Detalhes completos

Outros fatores diagnósticos

  • suicidality
  • cardiovascular symptoms
Detalhes completos

Fatores de risco

  • age >70 years
  • decreased renal clearance
  • hypokalemia (<3.0 to 3.5 mEq/L)
  • concomitant use of specific drugs
  • hypomagnesemia
  • hypercalcemia
  • hypothyroidism
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • ECG
  • digoxin serum concentration
  • serum potassium level
  • serum magnesium level
  • serum creatinine and BUN
Detalhes completos

Algoritmo de tratamento

AGUDA

acute ingestion, low to moderate toxicity

chronic ingestion, low to moderate toxicity

severe toxicity or hemodynamic compromise (acute or chronic toxicity)

CONTÍNUA

acute or chronic toxicity after initial treatment

Colaboradores

Consultores especialistas

Scott Phillips, MD

Associate Clinical Professor of Medicine

Department of Medicine

University of Colorado

Denver

CO

Clinical Assistant Professor

Department of Pharmacy

University of Washington

Seattle

WA

Chief Executive Officer/Medical Director

Washington Poison Center

Seattle

WA

Declarações

SP declares that he has no competing interests.

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge Dr Silas Smith for his advice on content in this topic.

Silas Smith MD, FACEP, FACMT

JoAnn G. and Kenneth Wellner Clinical Associate Professor of Emergency Medicine

NYU Langone

Ronald O. Perelman Department of Emergency Medicine

New York

NY

Declarações

SS's academic medicine organization has received U.S. federal research grants.

Agradecimentos

Dr Scott Phillips would like to gratefully acknowledge Dr Oladapo A. Odujube and Dr Robert S. Hoffman, previous contributors to this topic.

Declarações

OAO and RSH declare that they have no competing interests.

Revisores

Edward W. Boyer, MD

University of Massachusetts Medical School

Worcester

MA

Declarações

EWB declares that he has no competing interests.

Ruben Thanacoody, MD, FRCP(Edin)

Consultant Physician and Clinical Toxicologist

National Poisons Information Service (Newcastle)

Newcastle-upon-Tyne

UK

Declarações

RT declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Andrews P, Anseeuw K, Kotecha D, et al. Diagnosis and practical management of digoxin toxicity: a narrative review and consensus. Eur J Emerg Med. 2023 Dec 1;30(6):395-401.Texto completo  Resumo

Hack JB, Wingate S, Zolty R, et al. Expert consensus on the diagnosis and management of digoxin toxicity. Am J Med. 2025 Jan;138(1):25-33.e14.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Digoxin toxicity images
  • Diagnósticos diferenciais

    • Beta-blocker toxicity
    • Calcium-channel blocker toxicity
    • Clonidine toxicity
    Mais Diagnósticos diferenciais
  • Diretrizes

    • 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay
    • Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Heart attack

    Heart failure

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal